We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Palisade Bio Inc | NASDAQ:PALI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.68 | 1.88 | 4.71 | 0 | 09:09:34 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of Margery Fischbein to Board of Directors
On May 7, 2024 (the “Effective Date”), the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) appointed Margery Fischbein to the Board. On the Effective Date, pursuant to Ms. Fischbein’s appointment, the Board will have four (4) acting directors. Ms. Fischbein will serve until the Company’s 2024 annual meeting of shareholders or until such time as she resigns, is removed or her successor is appointed. Based upon a review of Ms. Fischbein’s questionnaire, Ms. Fischbein has been determined to be independent pursuant to Rule 10A-3(b) of the Securities Exchange Act of 1934, as amended and Nasdaq Rule 5605(a)(2) and further meets all of the qualifications to serve on an audit committee. Accordingly, Ms. Fischbein has been appointed to serve on the Company’s audit committee as of the Effective Date. In connection with her appointment to the Board, Ms. Fischbein will enter into the Company’s standard indemnification agreement.
There are no family relationships among Ms. Fischbein and any of our executive officers or directors and there are no transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Board Compensation
As compensation for her services on the Board, with respect to cash compensation, Ms. Fischbein will participate in the Company’s non-executive board compensation plan as described in the definitive proxy statement filed with the Securities Exchange Commission on April 21, 2023, the description of which is incorporated herein by reference.
Additionally, on the Effective Date, in lieu of the Company’s standard non-executive board compensation with respect to equity grants, Ms. Fischbein received an option to purchase 1,000 shares of the Company’s common stock (the “Option”). The Option has a term of ten (10) years, an exercise price of $7.90 per share, and vests in equal quarterly installments over a three (3) year period. The Option was issued from the Company’s 2021 Equity Incentive Plan, as amended.
Item 8.01 Other Events
On May 7, 2024, the Company issued a press release announcing the appointment of Margery Fischbein to the Board. A copy of the press release is attached to this report as Exhibit 99.01.
Item 9.01 Financial Statement and Exhibits.
Exhibit No. | Description | |
99.01 | Press Release Dated May 7, 2024 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 10, 2024 | Palisade Bio, Inc. | |
/s/ J.D. Finley | ||
By: | J.D. Finley | |
Chief Executive Officer |
Exhibit 99.01
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally
Carlsbad, CA – May 7, 2024 – Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors.
Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive.
“We are excited to welcome Margery to our Board of Directors. With her expertise and deep Wall Street and healthcare industry network we believe she will be a valuable asset and play a critical role as we continue to advance Palisade Bio’s strategy and our pipeline of novel therapeutics. We look forward to leveraging her strategic perspective to execute on our corporate objectives,” commented J.D. Finley, Chief Executive Officer of Palisade.
Ms. Fischbein added, “The Palisade team has established a path forward in a highly compelling area of drug development, identifying a precision medicine approach for redefining ulcerative colitis (UC) treatment through targeted interventions using PDE4-related biomarkers. I look forward to working closely with the Palisade team as we elevate this innovative approach with key players in the industry, build momentum and drive value for stakeholders in the near and long term.”
Ms. Fischbein currently serves as Managing Director, Healthcare, for Cassel Salpeter & Co., an independent investment banking firm. Previously, Ms. Fischbein was Head of Healthcare Investment Banking for Seaport Global and for FBR & Co. and Head of East Coast Biotechnology Investment Banking for JMP Securities. Prior to rejoining the banking industry, Ms. Fischbein held senior corporate positions at ImClone Systems and Human Genome Sciences. Early in her career, Ms. Fischbein was senior vice president at Lehman Brothers, and then was a Managing Director of investment banking at the Chase Manhattan Corporation and at Citigroup. Ms. Fischbein earned a master’s degree in business administration from Harvard Business School and a bachelor’s degree in economics from Harvard University.
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com
Cover |
May 10, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | May 10, 2024 |
Entity File Number | 001-33672 |
Entity Registrant Name | PALISADE BIO, INC. |
Entity Central Index Key | 0001357459 |
Entity Tax Identification Number | 52-2007292 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 7750 El Camino Real |
Entity Address, Address Line Two | Suite 2A |
Entity Address, City or Town | Carlsbad |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92009 |
City Area Code | (858) |
Local Phone Number | 704-4900 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.01 per share |
Trading Symbol | PALI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Palisade Bio Chart |
1 Month Palisade Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions